Griffin, Adrian D.; Perry, Andrew S.; Fleming, Douglas M. - In: PharmacoEconomics 19 (2001) 3, pp. 293-301
Objective: To evaluate the cost effectiveness of zanamivir 10mg twice daily for 5 days in the treatment of influenza in high-risk patients. Design: Bootstrap cost-effectiveness analysis incorporating within-trial analysis of pooled patient-level cost and effect data. Setting: UK unit costs and...